Toll-like receptor 4 (TLR4) inhibitors: Current research and prospective

Y Zhang, X Liang, X Bao, W Xiao, G Chen - European journal of medicinal …, 2022 - Elsevier
Abstract Toll-like receptor 4 (TLR4), a member of the Toll-like receptor (TLR) family, is
involved in innate immunity and mediates inflammatory responses by recognizing …

Post-COVID-19 syndrome

JD Pierce, Q Shen, SA Cintron, JB Hiebert - Nursing research, 2022 - journals.lww.com
Background Since the beginning of the coronavirus disease 2019 (COVID-19) pandemic,
many individuals have reported persistent symptoms and/or complications lasting beyond 4 …

Melatonin: A mitochondrial resident with a diverse skill set

RJ Reiter, R Sharma, S Rosales-Corral… - Life Sciences, 2022 - Elsevier
Melatonin is an ancient molecule that originated in bacteria. When these prokaryotes were
phagocytized by early eukaryotes, they eventually developed into mitochondria and …

Early identification, accurate diagnosis, and treatment of silicosis

T Li, X Yang, H Xu, H Liu - Canadian respiratory journal, 2022 - Wiley Online Library
Silicosis is a global problem, and it has brought about great burdens to society and patients'
families. The etiology of silicosis is clear, preventable, and controllable, but the onset is …

Therapeutic targeting of TLR4 for inflammation, infection, and cancer: a perspective for disaccharide lipid A mimetics

H Heine, A Zamyatina - Pharmaceuticals, 2022 - mdpi.com
The Toll-like receptor 4 (TLR4) signaling pathway plays a central role in the prompt defense
against infectious challenge and provides immediate response to Gram-negative bacterial …

Astragalus polysaccharide attenuates bleomycin-induced pulmonary fibrosis by inhibiting TLR4/NF-κB signaling pathway and regulating gut microbiota

Y Wei, M Qi, C Liu, L Li - European Journal of Pharmacology, 2023 - Elsevier
Purpose Astragalus polysaccharide (APS) is a naturally-occurring compound derived from
Astragalus membranaceus with anti-inflammatory and antioxidant properties. However, its …

HSP47: a therapeutic target in pulmonary fibrosis

N Sakamoto, D Okuno, T Tokito, H Yura, T Kido… - Biomedicines, 2023 - mdpi.com
Idiopathic pulmonary fibrosis (IPF) is a chronic lung disease characterized by a progressive
decline in lung function and poor prognosis. The deposition of the extracellular matrix (ECM) …

New natural pro-inflammatory cytokines (TNF-α, IL-6 and IL-1β) and iNOS inhibitors identified from Penicillium polonicum through in vitro and in vivo studies

PP Pal, AS Begum, SA Basha, H Araya… - International …, 2023 - Elsevier
Overexpression of pro-inflammatory cytokines and iNOS have been found to be concomitant
with several chronic inflammatory diseases and hence targeting their inhibition would be a …

[HTML][HTML] Dihydroartemisinin attenuates pulmonary inflammation and fibrosis in rats by suppressing JAK2/STAT3 signaling

X You, X Jiang, C Zhang, K Jiang, X Zhao… - Aging (Albany …, 2022 - ncbi.nlm.nih.gov
Abstract Coronavirus disease 2019 (COVID-19), caused by SARS-CoV-2, has induced a
worldwide pandemic since early 2020. COVID-19 causes pulmonary inflammation …

Prevention of bleomycin-induced pulmonary fibrosis by a RANKL peptide in mice

N Ju, H Hayashi, M Shimamura, S Baba, S Yoshida… - Scientific Reports, 2022 - nature.com
Despite the recent therapeutic developments for the treatment of pulmonary fibrosis, its
prognosis is still not well controlled, and a novel therapeutic agent is needed. Recently, the …